2'-O-Methylguanosine is a modified nucleoside produced in tRNAs by the action of tRNA guanosine-2’-O-methyltransferase. 2'-O-Methylguanosine results in apoptotic changes of cells.

DMT-2'Fluoro-DG(IB) Amidite (2'-F-ibu-dG Phosphoramidite) is a nucleoside that can be used in the preparation of 4'-modified 2'-deoxy-2'-fluorouridine.

DL-Tartaric acid is a non-racemic mixture of L- and D-tartaric acids with antioxidant activities.

3-Feruloylquinic acid, a derivative of quinic acid-bound phenolic acid, shows antioxidant activity. 3-Feruloylquinic acid markedly enhances by high photosynthetically active radiation (PAR) and UV irradiances.

(1R)-α-Pinene is a volatile monoterpene with antimicrobial activities. (1R)-α-Pinene reduces Bacillus cereus population growth, and exhibits repellent effects.

9-Phenanthrol (9-Hydroxyphenanthrene, Phenanthren-9-o, 9-Phenanthrenol) is a selective TRPM4 inhibitor with an IC50 in the range of 0.02 μM, without effects on TRPM5.

Dideoxyadenosine is konwn as 2′,3′-Dideoxyadenosine (ddA), a specific adenylyl cyclase inhibitor, is useful in biological process and pathway studies involving adenylyl cyclase activity and cAMP pool modulation.

Zinc acetate dihydrate (Acetic acid zinc salt dihydrate, Dicarbomethoxyzinc dihydrate) contributes to the antiviral activity of microbicide gel through zinc targeting the reverse transcriptase.

Magnesium chloride can reduce the activated thromboplastin times.

Polytetrafluoroethylene (PTFE) is a biomedical material and has excellent non-stick properties with an exceptionally low coefficient of friction.

1-Cbz-3-Hydroxyazetidine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Cbz-3-Hydroxyazetidine is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

20-(tert-Butoxy)-20-oxoicosanoic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 20-(tert-Butoxy)-20-oxoicosanoic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs

Serratia marcescens nuclease is a nonspecific nuclease. Serratia marcescens nuclease has broad utility due to its potent digestive activity toward both DNA and RNA.

Glucose oxidase is used in the food and beverage industry as a preservative and stabilizer and is commonly derived from the fungus Aspergillus niger. Glucose oxidase can react with intracellular glucose and oxygen (O2) to produce hydrogen peroxide (H2O2) and gluconic acid, which can cut off the nutrition source of cancer cells and consequently inhibit their proliferation.

Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction.

Inhibitor of HSP90, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction

Pyrimidine is an endogenous metabolite. It is used to study the photoinduced ion chemistry of the halogenated pyrimidines, a class of prototype radiosensitizing molecules, and is also used to assess pyrimidine/purine asymmetry quantitatively.

FL118(10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin analog, is a potent and orally active inhibitor of Survivin. FL118 also selectively and independently inhibits three additional cancer-associated survival genes Mcl-1, XIAP, and cIAP2 in a p53 status-independent manner. FL118 displays potent antitumor activity and can be used in cancer research.

Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.

HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL.

MDL-811 (MDL811) is a potent, selective and allosteric SIRT6 activator with EC50 of 5.7 uM (activated SIRT6 deacetylation), two-fold greater activity than MDL-800 (EC50=12.3 uM, Cat# 35760).

Novel activator of SIRT6 deacetylation

p-Toluic acid (4-Methylbenzoic acid) is a methylbenzoic acid and can be used as an intermediate for the synthesis of para-aminomethylbenzoic acid (PAMBA), p-tolunitrile, etc. It also exhibits hepatotoxicological potential in humanised-liver mice.

IPN01203 is a potential first-in-class T cell‑activating fusion protein designed to selectively engage Vβ6 T cells through both the T cell receptor (TCR) and the IL‑15 receptor pathway. Rather than relying on broad, non‑specific T cell stimulation, this approach aims to enhance antitumor immunity by activating a more focused subset of the T cell repertoire.

JNJ-89862175 is an antibody-drug conjugate (ADC) directed against ENPP3, currently under development for the treatment of advanced solid tumors. This program highlights the potential of ENPP3 as a tumor-associated antigen for targeted payload delivery, expanding ADC development beyond more established surface targets in the field.

CID-078 is an orally bioavailable macrocyclic compound that binds to the RxL groove of both cyclin A and cyclin B. By engaging this conserved docking site, it blocks their interactions with multiple components of the cell cycle machinery. More specifically, this agent disrupts HP-RxL motif‑mediated protein–protein interactions within the cyclin A2/CDK2‑E2F1 and cyclin B1/CDK1‑MYT1 complexes. The resulting interference leads to cell cycle arrest and triggers apoptotic cell death in tumor cells.

HLX316 is a potential first-in-class glyco-editing biologic developed using Palleon's EAGLE platform. It is constructed by fusing a human-derived sialidase enzyme with a human anti-B7-H3 monoclonal antibody. By targeting B7-H3-expressing tumor cells, this agent drives their desialylation, thereby reversing glycosylation-mediated immune suppression within the tumor microenvironment.

AZD8359 is a STEAP2-targeting T-cell engager. STEAP2 is a highly specific prostate-associated surface antigen that is strongly expressed across all stages of prostate adenocarcinoma. Built on AstraZeneca’s TITAN platform, AZD8359 is engineered to bias activity toward CD8+ T cells. Its "2+1" antibody format favors CD8+ over CD4+ T cells, preserving tumor cell killing while reducing the risk of cytokine release syndrome and off-target toxicity.

This therapeutic candidate, known as EpiTAC, is a tissue-selective bispecific antibody developed for EGFR-driven cancers. It works by binding to ITGB6 (integrin subunit beta-6), which promotes the degradation of both wild-type and mutant forms of EGFR specifically within tumor tissues. This triggers lysosome-mediated protein breakdown, potentially expanding the reach of EGFR-targeted therapy beyond currently defined mutation-restricted patient populations.

GalNAc Lipid 1005 is a trivalent GalNAc-lipid conjugate designed for ASGPR-mediated hepatic delivery. It features a lysine-based scaffold covalently linked to three GalNAc moieties via a ​44-unit PEG spacer, anchored by a ​1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid tail.